Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

64.63
-1.8750-2.82%
Volume:1.06M
Turnover:68.60M
Market Cap:12.65B
PE:-18.11
High:66.41
Open:66.39
Low:63.70
Close:66.50
52wk High:93.42
52wk Low:52.75
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.03
PE(LYR):-17.07

Loading ...

BridgeBio Management Joins Fireside Chats at September Healthcare Investor Conferences

Reuters
·
Sep 01

Mizuho Raises Price Target on BridgeBio Pharma to $110 From $96, Keeps Outperform Rating

MT Newswires Live
·
Sep 01

White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies

MT Newswires Live
·
Sep 01

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Sep 01

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

BridgeBio Signs Voluntary Access and Affordability Agreement with US Government

Reuters
·
Sep 01

BridgeBio Pharma, - to Offer Attruby Via Medicare Part D Without Future Pricing Mandates

THOMSON REUTERS
·
Sep 01

BridgeBio Pharma - to Expand State Medicaid Access to Marketed Medicine Via Generous Model

THOMSON REUTERS
·
Sep 01

BridgeBio Pharma, - Agreement Does not Impact Forgingbridges Copay Assistance Program

THOMSON REUTERS
·
Sep 01

BridgeBio Pharma - Does not Expect Future Pricing Mandates; Terms Remain Confidential

THOMSON REUTERS
·
Sep 01

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

THOMSON REUTERS
·
Sep 01

BridgeBio Publishes Discover-ATTR Digital Registry Presentation on ATTR-CM Data Integration

Reuters
·
Aug 31

BridgeBio Pharma Currently Down Eight Consecutive Days, on Pace for Record Losing Streak

Dow Jones
·
Aug 31

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
Aug 31

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study

TIPRANKS
·
Aug 31

BridgeBio Pharma Doses First Patient in Trial Evaluating Long-Term Impact of Heart Disease Medicine

MT Newswires Live
·
Aug 26

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

TIPRANKS
·
Aug 26

BridgeBio Announces First Participant Dosed in Ascend-Attr, a Phase 3B/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in Attr-Cm

THOMSON REUTERS
·
Aug 26

13D Filings

Dow Jones
·
Aug 22

BridgeBio Pharma CEO Neil Kumar Disposes of USD 3.07 Million in Common Shares

Reuters
·
Aug 21